行情

DRNA

DRNA

Dicerna制药
NASDAQ

实时行情|Nasdaq Last Sale

16.39
+0.59
+3.73%
已收盘, 16:00 10/18 EDT
开盘
15.70
昨收
15.80
最高
16.52
最低
15.69
成交量
42.62万
成交额
--
52周最高
16.95
52周最低
9.31
市值
11.20亿
市盈率(TTM)
-11.9374
分时
5日
1月
3月
1年
5年

分析师评级

9位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

DRNA 新闻

  • 新股聚焦 | B站微博纷纷看好,IP手游第一股中手游登陆港交所
  • 新浪网.2小时前
  • 新东方财报前瞻:新财年会有开门红吗?
  • 华盛通.2小时前
  • 沪指震荡微升 高层密集表态加大开放
  • 新浪财经.3小时前
  • 美股前瞻 | 黄峥:拼多多GMV超京东;苹果提醒旧手机升级系统
  • 华盛通.3小时前

更多

所属板块

生物技术和医学研究
-1.17%
制药与医学研究
-0.94%

热门股票

名称
价格
涨跌幅

DRNA 简况

Dicerna Pharmaceuticals, Inc. is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. It is focused on development of RNAi-based therapeutics using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases and cardiovascular diseases. Its development programs include dacryocystorhinostomy (DCR)-PHXC for the treatment of primary hyperoxaluria (PH), which is in a Phase I clinical trial; DCR-HBVS for the treatment of chronic hepatitis B virus (HBV), which is in a Phase I clinical trial, and a product candidate against a rare liver disease. It also developed a wholly owned clinical candidate, DCR-BCAT, targeting the β-catenin oncogene. DCR-BCAT is delivered by its lipid nanoparticle (LNP) tumor delivery system, EnCore.
展开

Webull提供Dicerna Pharmaceuticals Inc的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。